Oncology
Breast Cancer (drugs J-Z)
(Kisqali®, Nerlynx™, Tykerb®, Xeloda®)

Information

Patient name: ______________________ DOB: ____________
Sex: ❑ Female ❑ Male SSN: ______________________
Language: ____________ Wt: _____ ❑kg ❑lbs Ht: _____❑cm ❑in
Address: ____
Apt/Suite: _____ City: ______________ State: _____ Zip: ______
Phone: __________________ Alternate: ____________________
Caregiver name: ___________________ Relation: _____________
Local pharmacy: ___________________ Phone: _____________
Insurance plan: _________________ Plan ID: ______________
Please fax a copy of front and back of the insurance card(s).

Prescriber + Shipping Information

Prescriber name: ______________________________________
NPI: ____
Address: ____
Apt/Suite: ______ City: ____________ State: _______ Zip: ______
Contact: ____
Phone: ____________________ Alternate: __________________
Fax: ____
Email: ____
If shipping to prescriber: ❑ First Fill ❑ Always Never

Clinical Information (Please fax all pertinent clinical and lab information)

Diagnosis (C00-D49): ____________________________________ Diagnosis date: ________________
Mutations: ❑ HER2 ❑______________ ER: ❑ Positive ❑ Negative PR: ❑ Positive ❑ Negative

Prior Therapy ❑ Yes ❑ No	Reason for Discontinuation of Therapy	Approximate Start Date	Approximate End Date
______________	______________	______________	______________
______________	______________	______________	______________
______________	______________	______________	______________

Comorbidities: ____
Concomitant Medications: ______________________________________
Allergies: ❑ NKDA ❑ Other: ___________________________________

Prescription

§Afinitor® and Ibrance® are listed alphabetically on respective enrollment form.§

Medication	Directions	Quantity	Refill
❑ **Kisqali® (ribociclib) Femara® (letrozole) Co-pack**	Take 600 mg of Kisqali® by mouth once daily on days 1-21 with 2.5 mg of Femara® by mouth once daily on days 1-28 of a 28-day cycle. ______________	63 x 200 mg tablets of Kisqali® 28 x 2.5 mg tablets of Femara® ______________	_____
Kisqali® (ribociclib)	Take 600 mg by mouth once daily on days 1-21 of a 28-day cycle ______________ Patient will be obtaining an aromatase inhibitor at: Diplomat (fill prescription below) ❑ Other pharmacy ❑ Not receiving (Reason:______________)	63 x 200 mg tablets ______________	_____
Nerlynx™ (neratinib)	Take 240 mg by mouth once daily with food Take _____ mg by mouth once daily with food	180 x 40 mg tablets _____ x 40 mg tablets	_____
Loperamide	Take 4 mg by mouth three times daily for days 1-14; then take 4 mg by mouth twice daily for days 15-30	148 x 2 mg capsules	0
	Take 4 mg by mouth twice daily for days 31-56	104 x 2 mg capsules	0
	Take 4 mg by mouth as needed (not to exceed 16 mg per day)	_____ x 2 mg capsules	_____
Tykerb® (lapatinib)	Take 1,250 mg by mouth once daily at least one hour before or after a meal Take 1,500 mg by mouth once daily at least one hour before or after a meal ❑ ______________	❑ 105 x 250 mg tablets 180 x 250 mg tablets ______________	_____
Xeloda® (capecitabine)	Take _______ mg (_______ mg/m2/dose x _______ m2) by mouth twice daily (every 12 hours) within 30 minutes after a meal on days 1-14 of a 21-day cycle ______________	❑ ____ x 150 mg tablets ____ x 500 mg tablets ❑ ______________	_____

Endocrine Therapy Options

Medication	Directions	Quantity	Refill
Evista® (raloxifene) Fareston® (toremifene) Nolvadex® (tamoxifen)			
Arimidex® (anastrozole) Aromasin® (exemestane) ❑ Femara® (letrozole)			
Faslodex® (fulvestrant)			

Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: ________________

Stamp signature not allowed, physician signature required.

Prescriber's Signature: ____ Date: ______________

I authorize Diplomat Pharmacy, Inc. and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to Diplomat Pharmacy, Inc.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 810.768.9178 or by emailing compliance@diplomat.is to obtain instructions as to the proper destruction of the transmitted material. Thank you. 07262017

Copyright © 2017 by Diplomat Pharmacy Inc. All rights reserved. Diplomat is a registered trademark of Diplomat Pharmacy Inc.